Table 4.
CTL/vehicle |
CTL/RG108 |
PD/vehicle |
PD/RG108 |
|||||
---|---|---|---|---|---|---|---|---|
Fold change | SEM | Fold change | SEM | Fold change | SEM | Fold change | SEM | |
Amg | ||||||||
Cacna1a | 1.01 | 0.05 | −1.02 | 0.07 | −1.13 | 0.04 | −1.12 | 0.05 |
Syt1 | 1.01 | 0.04 | 1.01 | 0.04 | −1.05 | 0.05 | −1.05 | 0.05 |
Syt2 | 1.02 | 0.07 | −1.09 | 0.09 | −1.24 | 0.11 | −1.12 | 0.05 |
Cacna1l | 1.01 | 0.06 | 1.10 | 0.06 | 1.10 | 0.12 | 1.05 | 0.06 |
Slc8a2 | 1.02 | 0.08 | 1.19 | 0.10 | 1.56 | 0.23 | 1.26 | 0.11 |
wnk2 | 1.01 | 0.05 | 1.08 | 0.06 | 1.19* | 0.05 | 1.32* | 0.14 |
Hipp | ||||||||
Cacna1a | 1.01 | 0.06 | 1.03 | 0.05 | 1.07 | 0.05 | 1.24 | 0.11 |
Syt1 | 1.01 | 0.04 | 1.15 | 0.03 | 1.25 | 0.05 | 1.09 | 0.08 |
Syt2 | 1.02 | 0.08 | 1.32 | 0.15 | 1.52* | 0.13 | 1.50* | 0.14 |
Cacna1l | 1.01 | 0.07 | 1.00 | 0.06 | 1.11 | 0.11 | 1.18 | 0.11 |
Slc8a2 | 1.02 | 0.08 | 1.05 | 0.06 | 1.20* | 0.06 | 1.17* | 0.05 |
Wnk2 | 1.01 | 0.06 | 0.81 | 0.04 | 1.29* | 0.16 | 1.01 | 0.05 |
NAc | ||||||||
Cacna1a | 1.12 | 0.19 | 1.29 | 0.12 | 1.30 | 0.15 | 1.19 | 0.13 |
Syt1 | 1.09 | 0.17 | 1.19 | 0.09 | 1.12 | 0.09 | 1.02 | 0.07 |
Syt2 | 1.24 | 0.38 | 1.53 | 0.23 | 1.85 | 0.49 | 1.42 | 0.26 |
Cacna1l | 1.02 | 0.08 | −1.06 | 0.08 | 1.00 | 0.10 | 0.88 | 0.09 |
Slc8a2 | 1.02 | 0.07 | −1.07 | 0.07 | −1.03 | 0.08 | −1.22 | 0.07 |
Wnk2 | 1.01 | 0.06 | −1.02 | 0.06 | 1.02 | 0.06 | −1.19 | 0.05 |
amRNA levels (fold change) of cacna1a, syt1, syt2, cacna1l, Slc8a2, and wnk2 in the Amg, NAc, and Hipp of control and PD rats treated with vehicle or RG108.
*p < 0.05, control versus PD rats.